(Boursier.com) — Valbiotis camped below 4 euros this Friday after having published its annual accounts which highlight
a solid cash flow of more than €25 million at the end of 2023. The financial year was marked clinically by the great success of the Phase II/III study on TOTUM-63 (prediabetes/type 2 diabetes); An acceleration of industrial and commercial structuring with a view to the first marketing of the food supplements in the portfolio; Commercial launch of ValbiotisPRO Cholesterol: first revenues expected from May 2024.
Cash flow of more than €25 million at the end of 2023 secures the financing of an ambitious roadmap.
Upcoming launches in France, international partnerships: a confirmed roadmap
The company is also preparing the marketing of TOTUM-854 on the French market in 2025, then of TOTUM-448. These launches will be made under the ValbiotisPRO brand and will follow the same commercial strategy as that deployed for ValbiotisPRO Cholesterol.
Internationally, for these three products (ValbiotisPRO Cholesterol, TOTUM-854, TOTUM-448), the objective remains the signing of one or more licensing agreements at global or regional level (excluding France). Discussions to this effect are currently underway, particularly on ValbiotisPRO Cholesterol, with several players in the nutrition and health sectors. Their realization remains a priority for Valbiotis in 2024…
Portzamparc recalls that the group has reached a tipping point from ‘R&D’ to the commercial phase, with the group’s first product about to take its first steps. The cash flow is comfortable enough to avoid resorting to dilutive financing, underlines the analyst who remains a buy on the file.
©2024 Boursier.com